<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061736</url>
  </required_header>
  <id_info>
    <org_study_id>EFC11072</org_study_id>
    <secondary_id>2009-016266-90</secondary_id>
    <nct_id>NCT01061736</nct_id>
  </id_info>
  <brief_title>Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients</brief_title>
  <acronym>RA-MOBILITY</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      Part A (dose ranging study):

      To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of
      signs and symptoms of rheumatoid arthritis at 12 weeks.

      Part B (pivotal study):

      To demonstrate that sarilumab added to MTX was effective in:

        -  reduction of signs and symptoms of rheumatoid arthritis at 24 weeks

        -  inhibition of progression of structural damage at 52 weeks

        -  improvement in physical function at 16 weeks

      Secondary Objectives:

      Part B:

      To demonstrate that sarilumab added to MTX was effective in induction of a major clinical
      response at 52 weeks

      To assess the safety of sarilumab added to MTX

      To document the pharmacokinetic profile of sarilumab added to MTX in participants with active
      rheumatoid arthritis who were inadequate responders to MTX therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration for a participant was 16-22 weeks (Part A) and 56-62 weeks (Part B)
      broken down as follows:

        -  Screening: Up to 4 weeks

        -  Treatment: 12 weeks (Part A) and 52 weeks (Part B)*

        -  Follow-up: 6 weeks (for participants who would not continue in the long-term extension
           study).

      '*' Participants successfully completing their treatment period would be offered the
      opportunity to enter the long term extension study LTS11210 (SARIL-RA-EXTEND) (NCT01146652).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>ACR20 response was defined, based on guidelines set forth by the American College of Rheumatology (ACR), as ≥20 % improvement in tender joint count and swollen joint count as well as ≥20% improvement in at least 3 of 5 following measures: C-Reactive Protein (CRP), Participant assessment of pain; Participant's global assessment of disease activity; Physician global assessment of disease activity; and Health Assessment Question-Disability Index (HAQ-DI). Missing data imputed by Last Observation Carried Forward (LOCF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Percentage of Participants Achieving ACR20 Response at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>ACR20 improvement responses were determined without imputation of missing post-baseline values. In addition data collected after treatment discontinuation or rescue was set to missing. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>HAQ-DI was a participant-reported questionnaire that assesses the difficulty of performing daily activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Overall score range from 0=least difficulty to 3=extreme difficulty. An increase in the score indicates a worsening of physical function while a decrease in the score represents improvement. Data collected after treatment discontinuation was set to missing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The Sharp method modified by D. van der Heijde involves separate scores for erosions and joint space narrowing based on radiographs to assess the degree of structural damage. Total score range from 0 (normal) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Missing data were imputed by the linear extrapolation method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Major clinical response was defined as an ACR70 response maintained for at least 24 consecutive weeks. ACR70 response uses the same criteria as for ACR20 but requires 70% improvement. In the primary approach, data collected after treatment discontinuation or rescue was set to missing. No imputation of missing post-baseline values was performed. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">1675</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Part A: SAR 100 mg qw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: SAR 150 mg qw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: SAR 100 mg q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: SAR 150 mg q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: SAR 200 mg q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo qw</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for sarilumab) qw on top of MTX for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 1: Non-selected Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Pharmaceutical form: solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Part A: SAR 100 mg qw</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg qw</arm_group_label>
    <arm_group_label>Part A: SAR 100 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 200 mg q2w</arm_group_label>
    <arm_group_label>Part B Cohort 1: Non-selected Doses</arm_group_label>
    <arm_group_label>Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_label>Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <other_name>SAR153191</other_name>
    <other_name>REGN88</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for sarilumab)</intervention_name>
    <description>Pharmaceutical form: solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Part A: SAR 100 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 200 mg q2w</arm_group_label>
    <arm_group_label>Part A: Placebo qw</arm_group_label>
    <arm_group_label>Part B Cohort 1: Non-selected Doses</arm_group_label>
    <arm_group_label>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Same weekly dose as received prior to enrollment</description>
    <arm_group_label>Part A: SAR 100 mg qw</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg qw</arm_group_label>
    <arm_group_label>Part A: SAR 100 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 200 mg q2w</arm_group_label>
    <arm_group_label>Part A: Placebo qw</arm_group_label>
    <arm_group_label>Part B Cohort 1: Non-selected Doses</arm_group_label>
    <arm_group_label>Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_label>Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_label>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>According to local standard</description>
    <arm_group_label>Part A: SAR 100 mg qw</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg qw</arm_group_label>
    <arm_group_label>Part A: SAR 100 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 150 mg q2w</arm_group_label>
    <arm_group_label>Part A: SAR 200 mg q2w</arm_group_label>
    <arm_group_label>Part A: Placebo qw</arm_group_label>
    <arm_group_label>Part B Cohort 1: Non-selected Doses</arm_group_label>
    <arm_group_label>Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_label>Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
    <arm_group_label>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Diagnosis of rheumatoid arthritis ≥3 months duration

          -  Active disease defined as:

               -  at least 8/68 tender joints and 6/66 swollen joints,

               -  high sensitivity C-reactive protein (hs-CRP) &gt;6 mg/l,

               -  continuous treatment with MTX for at least 12 weeks prior to baseline visit and
                  on stable dose for at least 6 weeks prior to screening visit.

        Part B only:

          -  Bone erosion based on documented X-ray prior to first study drug intake, or

          -  Cyclic Citrullinated Peptide (CCP) positive, or

          -  Rheumatoid Factor (RF) positive.

        Exclusion criteria:

          -  Age &lt;18 years or &gt;75 years.

          -  Treatment with disease-modifying antirheumatic drugs (DMARDs) other than MTX within 4
             weeks or 12 weeks prior to screening (depending on DMARDs).

          -  Past history of non-response to prior Tumor Necrosis Factor (TNF) or biologic
             treatment.

          -  Any past or current biologic agents for the treatment of rheumatoid arthritis within 3
             months.

          -  Use of parenteral glucocorticoids or intraarticular glucocorticoids within 4 weeks
             prior to screening visit.

          -  Use of oral glucocorticoid greater than 10mg/day or equivalent/day, or a change in
             dosage within 4 weeks prior to baseline visit.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark C Genovese, MD, Professor of Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Immunology and Rheumatology - Stanford University - USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TWJ Huizinga, Prof Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Dpt of Rheumatology - Leiden University Medical Center - The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840070</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840072</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840029</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840021</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>94354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840049</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840050</name>
      <address>
        <city>Dunedin</city>
        <state>Florida</state>
        <zip>34698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840041</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840067</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840048</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840063</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840060</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840028</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840027</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840018</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840046</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840015</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840073</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840055</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840066</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840071</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840056</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840068</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840044</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840065</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840062</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840058</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840016</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840025</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840022</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840012</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840020</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840069</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840074</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840061</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032005</name>
      <address>
        <city>Buenos Aires</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032007</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032008</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032006</name>
      <address>
        <city>Caba</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032002</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004BAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032003</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032012</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>B7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032011</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032010</name>
      <address>
        <city>Ramos Mejia</city>
        <zip>1704</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032001</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032004</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032009</name>
      <address>
        <city>Zarate</city>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036003</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036005</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036002</name>
      <address>
        <city>East Malvern</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036012</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036010</name>
      <address>
        <city>Garran</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036004</name>
      <address>
        <city>Heidelberg West</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036009</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036001</name>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036006</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036011</name>
      <address>
        <city>Sydney</city>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036014</name>
      <address>
        <city>Victoria Park</city>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036007</name>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040001</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040002</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 112002</name>
      <address>
        <city>Minsk</city>
        <zip>220037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 112001</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076008</name>
      <address>
        <city>Campinas</city>
        <zip>13015-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076012</name>
      <address>
        <city>Campinas</city>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076001</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076006</name>
      <address>
        <city>Goiania</city>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076010</name>
      <address>
        <city>Juiz De Fora</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076004</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076005</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076011</name>
      <address>
        <city>Salvador</city>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076002</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04039-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076003</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04230 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076013</name>
      <address>
        <city>Vitoria</city>
        <zip>29055 450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124004</name>
      <address>
        <city>Burlington</city>
        <zip>L7R 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124008</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>St. Catharines</city>
        <zip>L2N 7E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124005</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124001</name>
      <address>
        <city>Toronto</city>
        <zip>M9R 2Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124012</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152005</name>
      <address>
        <city>Osorno</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152010</name>
      <address>
        <city>Puerto Montt</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152012</name>
      <address>
        <city>Santiago</city>
        <zip>7500922</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152001</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152002</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152008</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152009</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152011</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152013</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152014</name>
      <address>
        <city>Talca</city>
        <zip>3460000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152004</name>
      <address>
        <city>Valdivia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152006</name>
      <address>
        <city>Vina Del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152007</name>
      <address>
        <city>Viña Del Mar</city>
        <zip>2570017</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170004</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170001</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170008</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170003</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170006</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170007</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170009</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170002</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203005</name>
      <address>
        <city>Brno</city>
        <zip>63801</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203004</name>
      <address>
        <city>Hlucin</city>
        <zip>74801</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Praha 2</city>
        <zip>12850</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 818001</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 818002</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 233001</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 233002</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246001</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246002</name>
      <address>
        <city>Hyvinkää</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246003</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276007</name>
      <address>
        <city>Berlin</city>
        <zip>12161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276008</name>
      <address>
        <city>Berlin</city>
        <zip>12161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276004</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276015</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276005</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276013</name>
      <address>
        <city>Hamburg</city>
        <zip>22147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276012</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276006</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300002</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300003</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348006</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348014</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348003</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348010</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348011</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348013</name>
      <address>
        <city>Gy?r</city>
        <zip>9025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348015</name>
      <address>
        <city>Szombathely</city>
        <zip>H-9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348005</name>
      <address>
        <city>Sátoraljaújhely</city>
        <zip>3980</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348004</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356015</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356007</name>
      <address>
        <city>Bangalore</city>
        <zip>560079</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356003</name>
      <address>
        <city>Chennai</city>
        <zip>600004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356012</name>
      <address>
        <city>Hyderabad</city>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356005</name>
      <address>
        <city>Hyderabad</city>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356011</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356013</name>
      <address>
        <city>Lucknow</city>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356001</name>
      <address>
        <city>Maharashtra</city>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356010</name>
      <address>
        <city>Mumbai</city>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356004</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356002</name>
      <address>
        <city>New Delhi</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356008</name>
      <address>
        <city>New Delhi</city>
        <zip>76</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410014</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410006</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410004</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410013</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410005</name>
      <address>
        <city>Daejeon</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410010</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410009</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410001</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410011</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410007</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410012</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410003</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410002</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410008</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 440001</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 440002</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 458001</name>
      <address>
        <city>Ipoh</city>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 458002</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 458003</name>
      <address>
        <city>Putrajaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484008</name>
      <address>
        <city>Durango</city>
        <zip>34270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484004</name>
      <address>
        <city>Merida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484009</name>
      <address>
        <city>Merida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484007</name>
      <address>
        <city>Metepec</city>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>Mexico City</city>
        <zip>6726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484005</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528002</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 554004</name>
      <address>
        <city>Christchurch</city>
        <zip>8002</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 554002</name>
      <address>
        <city>Rotorua</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 554003</name>
      <address>
        <city>Tauranga</city>
        <zip>3001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 554001</name>
      <address>
        <city>Timaru</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 578004</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 578006</name>
      <address>
        <city>Tønsberg</city>
        <zip>3105</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 608003</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 608001</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 608002</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616002</name>
      <address>
        <city>Bialystok</city>
        <zip>15-354</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616003</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616001</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616005</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616006</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616004</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616012</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620003</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620001</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620002</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642006</name>
      <address>
        <city>Braila</city>
        <zip>810019</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642004</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642010</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642001</name>
      <address>
        <city>Bucuresti</city>
        <zip>010976</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642002</name>
      <address>
        <city>Bucuresti</city>
        <zip>020983</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642003</name>
      <address>
        <city>Bucuresti</city>
        <zip>400347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642005</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642008</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643017</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643006</name>
      <address>
        <city>Kemerovo</city>
        <zip>650099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643004</name>
      <address>
        <city>Moscow</city>
        <zip>107014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643020</name>
      <address>
        <city>Moscow</city>
        <zip>115404</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643001</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643002</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643012</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643009</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643016</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643014</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643010</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643011</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643007</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643008</name>
      <address>
        <city>St-Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643013</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710011</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710007</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710009</name>
      <address>
        <city>Cape Town</city>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710003</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710002</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710001</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710004</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710005</name>
      <address>
        <city>Pretoria</city>
        <zip>0075</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710006</name>
      <address>
        <city>Pretoria</city>
        <zip>0182</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710008</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710010</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724010</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724009</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724011</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724012</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Sevilla</city>
        <zip>41008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158002</name>
      <address>
        <city>Linkou</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158001</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 764001</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 764003</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792003</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792002</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792005</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792004</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792001</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804003</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804002</name>
      <address>
        <city>Donetsk</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804010</name>
      <address>
        <city>Kharkov</city>
        <zip>61022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804008</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804004</name>
      <address>
        <city>Kyiv</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804005</name>
      <address>
        <city>Lviv</city>
        <zip>79005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804006</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804009</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016 Sep 6;18:198. doi: 10.1186/s13075-016-1096-9.</citation>
    <PMID>27600829</PMID>
  </reference>
  <results_reference>
    <citation>Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014 Sep;73(9):1626-34. doi: 10.1136/annrheumdis-2013-204405. Epub 2013 Dec 2.</citation>
    <PMID>24297381</PMID>
  </results_reference>
  <results_reference>
    <citation>Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NM, Stahl N, Yancopoulos GD, Huizinga TW, van der Heijde D. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015 Jun;67(6):1424-37. doi: 10.1002/art.39093.</citation>
    <PMID>25733246</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <results_first_submitted>May 23, 2017</results_first_submitted>
  <results_first_submitted_qc>June 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <disposition_first_submitted>November 19, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 9, 2014</disposition_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 247 centers in 36 countries. Overall, 3715 participants were screened between March 2010 and July 2012, 2040 of whom were screen failures. Screen failures were mainly due to failure to meet the inclusion criterion for severity of the disease and/or due to meeting the exclusion criterion.</recruitment_details>
      <pre_assignment_details>Randomization was performed centrally with allocation generated by Interactive Voice/Web Response System, stratified by geographical region and prior biological use. 306 participants were randomized in Part A. 1369 participants were randomized in part B, 172 before dose selection (cohort 1) and 1197 after dose selection (cohort 2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: SAR 100 mg qw</title>
          <description>Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of methotrexate (MTX) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Part A: SAR 150 mg qw</title>
          <description>Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Part A: SAR 100 mg q2w</title>
          <description>Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Part A: SAR 150 mg q2w</title>
          <description>Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Part A: SAR 200 mg q2w</title>
          <description>Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Part A: Placebo qw</title>
          <description>Placebo (for sarilumab) qw on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Part B Cohort 1: Non-selected Doses</title>
          <description>Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).</description>
        </group>
        <group group_id="P8">
          <title>Part B: SAR 150 mg q2w (Cohort 1 [Selected Dose]+Cohort 2)</title>
          <description>Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with high dose of sarilumab (SAR 200 mg q2w).</description>
        </group>
        <group group_id="P9">
          <title>Part B: SAR 200 mg q2w (Cohort 1 [Selected Dose]+Cohort 2)</title>
          <description>Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with high dose of sarilumab (SAR 200 mg q2w).</description>
        </group>
        <group group_id="P10">
          <title>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with high dose of sarilumab (SAR 200 mg q2w).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="84"/>
                <participants group_id="P8" count="430"/>
                <participants group_id="P9" count="427"/>
                <participants group_id="P10" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="84"/>
                <participants group_id="P8" count="428"/>
                <participants group_id="P9" count="426"/>
                <participants group_id="P10" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rescued</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="61">Included both participants who completed and did not complete the study.</participants>
                <participants group_id="P9" count="55">Included both participants who completed and did not complete the study.</participants>
                <participants group_id="P10" count="168">Included both participants who completed and did not complete the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="49"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="336"/>
                <participants group_id="P9" count="330"/>
                <participants group_id="P10" count="354"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="84"/>
                <participants group_id="P8" count="94"/>
                <participants group_id="P9" count="97"/>
                <participants group_id="P10" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dose regimen not selected</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="79"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="63"/>
                <participants group_id="P9" count="67"/>
                <participants group_id="P10" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="18"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: SAR 100 mg qw</title>
          <description>Sarilumab 100 mg SC injection qw on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Part A: SAR 150 mg qw</title>
          <description>Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Part A: SAR 100 mg q2w</title>
          <description>Sarilumab 100 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Part A: SAR 150 mg q2w</title>
          <description>Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Part A: SAR 200 mg q2w</title>
          <description>Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Part A: Placebo qw</title>
          <description>Placebo (for sarilumab) qw on top of MTX for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Part B Cohort 1: Non-selected Doses</title>
          <description>Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).</description>
        </group>
        <group group_id="B8">
          <title>Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with high dose of sarilumab (SAR 200 mg q2w).</description>
        </group>
        <group group_id="B9">
          <title>Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with high dose of sarilumab (SAR 200 mg q2w).</description>
        </group>
        <group group_id="B10">
          <title>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with high dose of sarilumab (SAR 200 mg q2w).</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="52"/>
            <count group_id="B7" value="84"/>
            <count group_id="B8" value="430"/>
            <count group_id="B9" value="427"/>
            <count group_id="B10" value="428"/>
            <count group_id="B11" value="1675"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="12.3"/>
                    <measurement group_id="B2" value="50.9" spread="11.1"/>
                    <measurement group_id="B3" value="53.5" spread="11.8"/>
                    <measurement group_id="B4" value="51.2" spread="12.9"/>
                    <measurement group_id="B5" value="48.7" spread="12.4"/>
                    <measurement group_id="B6" value="55.2" spread="12.5"/>
                    <measurement group_id="B7" value="51.1" spread="11.5"/>
                    <measurement group_id="B8" value="50.3" spread="11.9"/>
                    <measurement group_id="B9" value="50.8" spread="12.0"/>
                    <measurement group_id="B10" value="51.1" spread="11.2"/>
                    <measurement group_id="B11" value="51.04" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="69"/>
                    <measurement group_id="B8" value="345"/>
                    <measurement group_id="B9" value="359"/>
                    <measurement group_id="B10" value="346"/>
                    <measurement group_id="B11" value="1362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="85"/>
                    <measurement group_id="B9" value="68"/>
                    <measurement group_id="B10" value="82"/>
                    <measurement group_id="B11" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>ACR20 response was defined, based on guidelines set forth by the American College of Rheumatology (ACR), as ≥20 % improvement in tender joint count and swollen joint count as well as ≥20% improvement in at least 3 of 5 following measures: C-Reactive Protein (CRP), Participant assessment of pain; Participant's global assessment of disease activity; Physician global assessment of disease activity; and Health Assessment Question-Disability Index (HAQ-DI). Missing data imputed by Last Observation Carried Forward (LOCF).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Part A Intent-to-treat (ITT) population defined as all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: SAR 100 mg qw</title>
            <description>Sarilumab 100 mg SC injection qw on top of MTX for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: SAR 150 mg qw</title>
            <description>Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: SAR 100 mg q2w</title>
            <description>Sarilumab 100 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: SAR 150 mg q2w</title>
            <description>Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: SAR 200 mg q2w</title>
            <description>Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Placebo qw</title>
            <description>Placebo (for sarilumab) qw on top of MTX for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>ACR20 response was defined, based on guidelines set forth by the American College of Rheumatology (ACR), as ≥20 % improvement in tender joint count and swollen joint count as well as ≥20% improvement in at least 3 of 5 following measures: C-Reactive Protein (CRP), Participant assessment of pain; Participant's global assessment of disease activity; Physician global assessment of disease activity; and Health Assessment Question-Disability Index (HAQ-DI). Missing data imputed by Last Observation Carried Forward (LOCF).</description>
          <population>Part A Intent-to-treat (ITT) population defined as all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="65.4"/>
                    <measurement group_id="O6" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using two-sided Cochran-Mantel-Haenszel test. Pairwise comparisons of the response rates between each dose of sarilumab and placebo were derived. The multiplicity issues were addressed by using the Hommel-procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1155</p_value>
            <p_value_desc>Threshold for significance = 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <p_value_desc>Threshold for significance = 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>9.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7119</p_value>
            <p_value_desc>Threshold for significance = 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0363</p_value>
            <p_value_desc>Threshold for significance = 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>5.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0426</p_value>
            <p_value_desc>Threshold for significance = 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>5.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Percentage of Participants Achieving ACR20 Response at Week 24</title>
        <description>ACR20 improvement responses were determined without imputation of missing post-baseline values. In addition data collected after treatment discontinuation or rescue was set to missing. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>ITT population which included all participants randomized after dose selection (cohort 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: SAR 150 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: SAR 200 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Placebo q2w</title>
            <description>Participants randomized after dose selection received Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Percentage of Participants Achieving ACR20 Response at Week 24</title>
          <description>ACR20 improvement responses were determined without imputation of missing post-baseline values. In addition data collected after treatment discontinuation or rescue was set to missing. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.</description>
          <population>ITT population which included all participants randomized after dose selection (cohort 2).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="399"/>
                <count group_id="O3" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="66.4"/>
                    <measurement group_id="O3" value="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using two-sided Cochran-Mantel-Haenszel test. Pairwise comparisons of the response rates between each dose of sarilumab and placebo was derived. The multiplicity issues for part B were addressed by using a Bonferroni correction for each dose together with a hierarchical testing procedure across the 3 co-primary and the main secondary endpoints. The hierarchical testing sequence continued only when previous endpoint was statistically significant at 0.025 level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.773</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.077</ci_lower_limit>
            <ci_upper_limit>3.703</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.975</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.957</ci_lower_limit>
            <ci_upper_limit>5.344</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16</title>
        <description>HAQ-DI was a participant-reported questionnaire that assesses the difficulty of performing daily activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Overall score range from 0=least difficulty to 3=extreme difficulty. An increase in the score indicates a worsening of physical function while a decrease in the score represents improvement. Data collected after treatment discontinuation was set to missing.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Cohort 2 ITT population only and included participants with available data of HAQ-DI at baseline and on or before Week 16.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: SAR 150 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: SAR 200 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Placebo q2w</title>
            <description>Participants randomized after dose selection received Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16</title>
          <description>HAQ-DI was a participant-reported questionnaire that assesses the difficulty of performing daily activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Overall score range from 0=least difficulty to 3=extreme difficulty. An increase in the score indicates a worsening of physical function while a decrease in the score represents improvement. Data collected after treatment discontinuation was set to missing.</description>
          <population>Cohort 2 ITT population only and included participants with available data of HAQ-DI at baseline and on or before Week 16.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.63"/>
                    <measurement group_id="O2" value="1.69" spread="0.63"/>
                    <measurement group_id="O3" value="1.61" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.67"/>
                    <measurement group_id="O2" value="1.11" spread="0.7"/>
                    <measurement group_id="O3" value="1.31" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.55"/>
                    <measurement group_id="O2" value="-0.58" spread="0.63"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using a mixed model for repeated measures (MMRM). Differences in least square (LS) mean between each dose of sarilumab and placebo were derived. Testing was performed according to the hierarchical testing procedure (performed only when the previous endpoint was statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.312</ci_lower_limit>
            <ci_upper_limit>-0.157</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.258</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.336</ci_lower_limit>
            <ci_upper_limit>-0.181</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52</title>
        <description>The Sharp method modified by D. van der Heijde involves separate scores for erosions and joint space narrowing based on radiographs to assess the degree of structural damage. Total score range from 0 (normal) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Missing data were imputed by the linear extrapolation method.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Cohort 2 ITT population and included participants with available data of mTSS at baseline and on or before Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: SAR 150 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: SAR 200 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Placebo q2w</title>
            <description>Participants randomized after dose selection received Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52</title>
          <description>The Sharp method modified by D. van der Heijde involves separate scores for erosions and joint space narrowing based on radiographs to assess the degree of structural damage. Total score range from 0 (normal) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Missing data were imputed by the linear extrapolation method.</description>
          <population>Cohort 2 ITT population and included participants with available data of mTSS at baseline and on or before Week 52.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.67" spread="63.42"/>
                    <measurement group_id="O2" value="46.34" spread="57.43"/>
                    <measurement group_id="O3" value="48.01" spread="65.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.57" spread="63.73"/>
                    <measurement group_id="O2" value="46.59" spread="57.63"/>
                    <measurement group_id="O3" value="50.79" spread="65.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="4.66"/>
                    <measurement group_id="O2" value="0.25" spread="4.61"/>
                    <measurement group_id="O3" value="2.78" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using two-sided rank-based ANCOVA model. Testing was performed according to the hierarchical testing procedure (performed only when the previous endpoints were statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Rank ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Rank ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52</title>
        <description>Major clinical response was defined as an ACR70 response maintained for at least 24 consecutive weeks. ACR70 response uses the same criteria as for ACR20 but requires 70% improvement. In the primary approach, data collected after treatment discontinuation or rescue was set to missing. No imputation of missing post-baseline values was performed. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT population which included all participants randomized after dose selection (cohort 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: SAR 150 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: SAR 200 mg q2w</title>
            <description>Participants randomized after dose selection received Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Placebo q2w</title>
            <description>Participants randomized after dose selection received Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52</title>
          <description>Major clinical response was defined as an ACR70 response maintained for at least 24 consecutive weeks. ACR70 response uses the same criteria as for ACR20 but requires 70% improvement. In the primary approach, data collected after treatment discontinuation or rescue was set to missing. No imputation of missing post-baseline values was performed. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.</description>
          <population>ITT population which included all participants randomized after dose selection (cohort 2).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="399"/>
                <count group_id="O3" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using two-sided Cochran-Mantel-Haenszel test. Pairwise comparisons of the response rates between each dose of sarilumab and placebo were derived. Testing was performed according to the hierarchical testing procedure (performed only when the previous endpoints were statistically significant).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.661</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.451</ci_lower_limit>
            <ci_upper_limit>8.863</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance = 0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.565</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.946</ci_lower_limit>
            <ci_upper_limit>10.515</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected from signature of the informed consent form up to study completion regardless of seriousness or relationship to investigational medicinal product (IMP).</time_frame>
      <desc>Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the ‘on treatment period' (from the first IMP injection up to the end of the study). Safety population defined as all randomized participants who received at least one dose of IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: SAR 100 mg qw</title>
          <description>Part A participants exposed to sarilumab 100 mg qw on top of MTX (mean exposure of 10 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Part A: SAR 150 mg qw</title>
          <description>Part A participants exposed to sarilumab 150 mg qw on top of MTX (mean exposure of 12 weeks).</description>
        </group>
        <group group_id="E3">
          <title>Part A: SAR 100 mg q2w</title>
          <description>Part A participants exposed to sarilumab 100 mg q2w on top of MTX (mean exposure of 11 weeks).</description>
        </group>
        <group group_id="E4">
          <title>Part A: SAR 150 mg q2w</title>
          <description>Part A participants exposed to sarilumab 150 mg q2w on top of MTX (mean exposure of 12 weeks). Included the participant randomized to placebo qw who received sarilumab 150 mg q2w in error.</description>
        </group>
        <group group_id="E5">
          <title>Part A: SAR 200 mg q2w</title>
          <description>Part A participants exposed to sarilumab 200 mg q2w on top of MTX (mean exposure of 11 weeks).</description>
        </group>
        <group group_id="E6">
          <title>Part A: Placebo qw</title>
          <description>Part A participants exposed to placebo on top of MTX (mean exposure of 12 weeks). Excluded 1 participant who received an erroneous IMP kit with sarilumab 150 mg q2w. He/she was considered in the 150 mg q2w treatment group for safety analysis.</description>
        </group>
        <group group_id="E7">
          <title>Part B: SAR 100 mg qw Cohort 1 (Non-selected Dose)</title>
          <description>Part B participants exposed to sarilumab 100 mg qw on top of MTX (mean exposure of 10 weeks).</description>
        </group>
        <group group_id="E8">
          <title>Part B: SAR 150 mg qw Cohort 1 (Non-selected Dose)</title>
          <description>Part B participants exposed to sarilumab 150 mg qw on top of MTX (mean exposure of 12 weeks). Excluded 1 participant who received sarilumab 100 mg q2w in error. He/she was considered in the 100 mg q2w treatment group for safety analysis.</description>
        </group>
        <group group_id="E9">
          <title>Part B: SAR 100 mg q2w Cohort 1 (Non-selected Dose)</title>
          <description>Part B participants exposed to sarilumab 100 mg q2w on top of MTX (mean exposure of 13 weeks). Included 1 participant who received sarilumab 100 mg q2w in error.</description>
        </group>
        <group group_id="E10">
          <title>Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Part B participants exposed to sarilumab 150 mg q2w on top of MTX (mean exposure of 42 weeks). 61 participants with inadequate response from Week 16 rescued with high dose of sarilumab (SAR 200 mg q2w) were not included. Included 3 participants randomized to sarilumab 200 mg q2w who received at least one dose of sarilumab 150 mg q2w in error.</description>
        </group>
        <group group_id="E11">
          <title>Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Part B participants exposed to sarilumab 200 mg q2w on top of MTX (mean exposure of 42 weeks). 55 participants with inadequate response from Week 16 rescued with high dose of sarilumab (SAR 200 mg q2w) were not included. Excluded 3 participants randomized to sarilumab 200 mg q2w who received at least one dose of sarilumab 150 mg q2w in error and included a participant randomized to placebo q2w who received sarilumab 200 mg q2w in error.</description>
        </group>
        <group group_id="E12">
          <title>Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)</title>
          <description>Part B participants exposed to placebo q2w on top of MTX (mean exposure of 40 weeks). 168 participants with inadequate response from Week 16 rescued with high dose of sarilumab (SAR 200 mg q2w) were not included. Excluded 1 participant randomized to placebo q2w who received sarilumab 200 mg q2w in error. He/she was considered in the 200 mg q2w treatment group for safety analysis.</description>
        </group>
        <group group_id="E13">
          <title>Part B Sarilumab Rescue: Cohort 1(Selected Doses)+Cohort2</title>
          <description>Part B participants exposed to sarilumab 150 mg q2w or 200 mg q2w or placebo q2w, without adequate response from Week 16, rescued with high dose of sarilumab (SAR 200 mg q2w) (mean exposure of 49 weeks from beginning of randomization to the end of rescue treatment).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="35" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="46" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="21" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abdominal wall hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastric ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Immediate post-injection reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Subacute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Wound hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neoplasm of appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Shock hemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="163" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="194" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="95" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="83" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="36" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="55" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="24" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="31" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="35" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="22" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="26" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="31" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="30" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="370"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="369"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="259"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

